LEADER 04937nam 22008295 450 001 9910438014903321 005 20200701072150.0 010 $a1-907673-94-6 024 7 $a10.1007/978-1-907673-94-8 035 $a(CKB)3710000000119077 035 $a(EBL)1782082 035 $a(SSID)ssj0001243251 035 $a(PQKBManifestationID)11838309 035 $a(PQKBTitleCode)TC0001243251 035 $a(PQKBWorkID)11268760 035 $a(PQKB)10635325 035 $a(DE-He213)978-1-907673-94-8 035 $a(MiAaPQ)EBC1782082 035 $a(PPN)178779695 035 $a(EXLCZ)993710000000119077 100 $a20140528d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aHandbook of HER2-targeted agents in breast cancer$b[electronic resource] /$fby Ricardo H Alvarez, Javier Cortés, Leticia Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Stefania Zambelli, Dimitrios Zardavas 205 $a1st ed. 2013. 210 1$aTarporley :$cSpringer Healthcare Ltd. :$cImprint: Springer Healthcare,$d2013. 215 $a1 online resource (107 p.) 300 $aDescription based upon print version of record. 311 $a1-322-13345-X 311 $a1-907673-93-8 320 $aIncludes bibliographical references. 327 $aIntroduction and background biology -- HER2 testing -- HER2-positive breast cancer: adjuvant and neoadjuvant therapy -- HER2-positive metastatic breast cancer: first-line treatment -- HER2-positive metastatic breast cancer: second-line treatment -- Emerging targeted agents for HER2-positive breast cancer. 330 $aBreast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15?25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings. 606 $aOncology   606 $aPrimary care (Medicine) 606 $aGeneral practice (Medicine) 606 $aInternal medicine 606 $aPharmacotherapy 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aPrimary Care Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H51000 606 $aGeneral Practice / Family Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H24003 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 615 0$aOncology  . 615 0$aPrimary care (Medicine). 615 0$aGeneral practice (Medicine). 615 0$aInternal medicine. 615 0$aPharmacotherapy. 615 14$aOncology. 615 24$aPrimary Care Medicine. 615 24$aGeneral Practice / Family Medicine. 615 24$aInternal Medicine. 615 24$aPharmacotherapy. 676 $a616.99449 700 $aAlvarez$b Ricardo H$4aut$4http://id.loc.gov/vocabulary/relators/aut$0860186 702 $aCortés$b Javier$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aMattos-Arruda$b Leticia$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aFalzon$b Mary$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aFasolo$b Angelica$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aGandy$b Michael$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aGianni$b Luca$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aHarbeck$b Nadia$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aPiccart$b Martine$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aZambelli$b Stefania$4aut$4http://id.loc.gov/vocabulary/relators/aut 702 $aZardavas$b Dimitrios$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910438014903321 996 $aHandbook of HER2-targeted agents in breast cancer$91919318 997 $aUNINA